Overview
Background
Dr Hana Starobova is a pharmacist and NHMRC research fellow at the Sensory Neuropharmacology Group at the University of Queensland (UQ). She works under the mentorship of Prof. Vetter, and as an early career researcher, she is working toward an independent research career as a group leader. She obtained her PhD in 2020 from the Institute for Molecular Bioscience, UQ, and continued here to conduct studies as a Children Hospital Foundation Fellow (2021-2023) in the areas of cancer therapy-induced adverse and late effects with the main focus on neuropathies. Over the past four years, she has developed a research program focusing on the understanding of cancer therapy-induced adverse and late effects with a special interest in children, and established innovative transcriptomic and microscopy pipelines, in vitro assays, adult and juvenile models of adverse and late effects following mono- and combination chemotherapy and radiotherapy, assays for the assessment of adverse effects including cognition and neuropathies, as well as cancer models. Knowledge impact arising from her research program has been disseminated in 18 peer-reviewed publications, having together attracted >1,100 citations (h-index 15, i10-index 18, Google Scholar, May 2024).
Availability
- Dr Hana Starobova is:
- Available for supervision
Fields of research
Qualifications
- Doctor of Philosophy, The University of Queensland
Research interests
-
Development of mechanism based treatments of cancer therapy-induced adverse effects
-
Adhesion Molecules and Immunology
-
Adult and Juvenile In vivo preclinical models
-
Impact of age on cancer therapy-induced adverse effects
Research impacts
Dr Starobova`s work on the adverse effects of cancer therapy has led to several industry collaborations and industry-sponsored research programs, including a collaboration with Swedish Pharma Company Cantargia. Additionally, Dr Starobova is a consulting member of the Cancer Prevention Initiative Scientific Council, Washington DC. Dr Starobova`s research also attracted philanthropic funding from private donors, evidencing the relevance and importance of her research to patients.
Dr Starobova has won more than 15 awards and honours during her research career, including the following prestigious national and international awards: Women in Technology, Young Achiever Award winner (2019) for contribution to science, Best Abstract award in the allied health category, ANZCHOG (2023), International Association for the Study of Pain (IASP) Award - the 17th World Congress on Pain, Boston, USA (2018), State Pharmacists’ Association Medal for the highest-ranked master’s student of pharmacy at all universities in Germany (2015). Dr Starobova is also an alumna (2019) and a member of the Homeward Bound project community.
Works
Search Professor Hana Starobova’s works on UQ eSpace
2024
Journal Article
The Role of the Gut Microbiome in Neuroinflammation and Chemotherapy-Induced Peripheral Neuropathy
Shatunova, Svetlana, Aktar, Rubina, Peiris, Madusha, Lee, Jia Yu Peppermint, Vetter, Irina and Starobova, Hana (2024). The Role of the Gut Microbiome in Neuroinflammation and Chemotherapy-Induced Peripheral Neuropathy. European Journal of Pharmacology, 979 176818, 176818. doi: 10.1016/j.ejphar.2024.176818
2024
Conference Publication
Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data
Van Cutsem, Eric, Ochsenreither, Sebastian, Collignon, Joelle, Eefsen, Rikke Løvendahl, Ivanauskas, Audrius, Shatunova, Svetlana, Vetter, Irina, Gyllenbäck, Elin Jaensson, Skoog, Petter, Losic, Nedjad, Tersago, Dominique and Starobova, Hana (2024). Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.4148
2024
Conference Publication
Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data
Van Cutsem, Eric, Ochsenreither, Sebastian, Collignon, Joelle, Eefsen, Rikke Lovendahl, Ivanauskas, Audrius, Shatunova, Svetlana, Vetter, Irina, Gyllenback, Elin Jaensson, Skoog, Petter, Losic, Nedjad, Tersago, Dominique and Starobova, Hana (2024). Impact on chemotherapy induced peripheral neuropathy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in patients with pancreatic cancer, with supportive mouse model data. 2024 ASCO Annual Meeting Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary, Chicago, IL, United States, 31 May - 4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology.
2022
Journal Article
The role of the neuronal microenvironment in sensory function and pain pathophysiology
Starobova, Hana, Alshammari, Ammar, Winkler, Ingrid G. and Vetter, Irina (2022). The role of the neuronal microenvironment in sensory function and pain pathophysiology. Journal of Neurochemistry. doi: 10.1111/jnc.15724
2022
Journal Article
Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients
Tay, Nicolette, Laakso, E-Liisa, Schweitzer, Daniel, Endersby, Raelene, Vetter, Irina and Starobova, Hana (2022). Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients. Frontiers in Molecular Biosciences, 9 1015746, 1015746. doi: 10.3389/fmolb.2022.1015746
2022
Journal Article
A kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling
Stables, Jennifer, Green, Emma K., Sehgal, Anuj, Patkar, Omkar L., Keshvari, Sahar, Taylor, Isis, Ashcroft, Maisie E., Grabert, Kathleen, Wollscheid-Lengeling, Evi, Szymkowiak, Stefan, McColl, Barry W., Adamson, Antony, Humphreys, Neil E., Mueller, Werner, Starobova, Hana, Vetter, Irina, Shabestari, Sepideh Kiani, Blurton-Jones, Matthew M., Summers, Kim M., Irvine, Katharine M., Pridans, Clare and Hume, David A. (2022). A kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling. Development, 149 (8) dev200237. doi: 10.1242/dev.200237
2022
Journal Article
A peptide toxin in ant venom mimics vertebrate EGF-like hormones to cause long-lasting hypersensitivity in mammals
Eagles, David A., Saez, Natalie J., Krishnarjuna, Bankala, Bradford, Julia J., Chin, Yanni K.-Y., Starobova, Hana, Mueller, Alexander, Reichelt, Melissa E., Undheim, Eivind A. B., Norton, Raymond S., Thomas, Walter G., Vetter, Irina, King, Glenn F. and Robinson, Samuel D. (2022). A peptide toxin in ant venom mimics vertebrate EGF-like hormones to cause long-lasting hypersensitivity in mammals. Proceedings of the National Academy of Sciences, 119 (7) e2112630119. doi: 10.1073/pnas.2112630119
2022
Journal Article
Multitarget nociceptor sensitization by a promiscuous peptide from the venom of the King Baboon spider
Finol-Urdaneta, Rocio K., Ziegman, Rebekah, Dekan, Zoltan, McArthur, Jeffrey R., Heitmann, Stewart, Luna-Ramirez, Karen, Tae, Han-Shen, Mueller, Alexander, Starobova, Hana, Chin, Yanni K.-Y., Wingerd, Joshua S., Undheim, Eivind A. B., Cristofori-Armstrong, Ben, Hill, Adam P., Herzig, Volker, King, Glenn F., Vetter, Irina, Rash, Lachlan D., Adams, David J. and Alewood, Paul F. (2022). Multitarget nociceptor sensitization by a promiscuous peptide from the venom of the King Baboon spider. Proceedings of the National Academy of Sciences, 119 (5) e2110932119. doi: 10.1073/pnas.2110932119
2021
Journal Article
Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release
Starobova, Hana, Monteleone, Mercedes, Adolphe, Christelle, Batoon, Lena, Sandrock, Cheyenne J., Tay, Bryan, Deuis, Jennifer R., Smith, Alexandra V., Mueller, Alexander, Nadar, Evelyn Israel, Lawrence, Grace Pamo, Mayor, Amanda, Tolson, Elissa, Levesque, Jean-Pierre, Pettit, Allison R., Wainwright, Brandon J., Schroder, Kate and Vetter, Irina (2021). Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release. Journal of Experimental Medicine, 218 (5) e20201452. doi: 10.1084/jem.20201452
2021
Conference Publication
Subcutaneous analgesic actions and mode of action of binding of ω-conotoxins at Cav2.2
Hasan, Mahadhi, Abraham, Nikita, Cardoso, Fernanda C., Ragnarsson, Lotten, Starobova, Hana, Mueller, Alexander, Vetter, Irina and Lewis, Richard J. (2021). Subcutaneous analgesic actions and mode of action of binding of ω-conotoxins at Cav2.2. Venom to Drugs, Daydream Island, QLD Australia, 15 - 19 March 2021.
2021
Journal Article
Subcutaneous ω-conotoxins alleviate mechanical pain in rodent models of acute peripheral neuropathy
Hasan, Md. Mahadhi, Starobova, Hana, Mueller, Alexander, Vetter, Irina and Lewis, Richard J. (2021). Subcutaneous ω-conotoxins alleviate mechanical pain in rodent models of acute peripheral neuropathy. Marine Drugs, 19 (2) 106, 1-15. doi: 10.3390/md19020106
2021
Journal Article
Small cyclic sodium channel inhibitors
Peigneur, Steve, da Costa Oliveira, Cristina, de Sousa Fonseca, Flávia Cristina, McMahon, Kirsten L., Mueller, Alexander, Cheneval, Olivier, Cristina Nogueira Freitas, Ana, Starobova, Hana, Dimitri Gama Duarte, Igor, Craik, David J., Vetter, Irina, de Lima, Maria Elena, Schroeder, Christina I. and Tytgat, Jan (2021). Small cyclic sodium channel inhibitors. Biochemical Pharmacology, 183 114291, 114291. doi: 10.1016/j.bcp.2020.114291
2020
Journal Article
The NLRP3 inflammasome: role and therapeutic potential in pain treatment
Starobova, Hana, Nadar, Evelyn Israel and Vetter, Irina (2020). The NLRP3 inflammasome: role and therapeutic potential in pain treatment. Frontiers in Physiology, 11 1016, 1016. doi: 10.3389/fphys.2020.01016
2020
Other Outputs
Novel therapeutic targets for the treatment of vincristine induced peripheral neuropathy
Starobova, Hana (2020). Novel therapeutic targets for the treatment of vincristine induced peripheral neuropathy. PhD Thesis, Institute for Molecular Bioscience, The University of Queensland. doi: 10.14264/uql.2020.972
2020
Journal Article
Mapping the molecular surface of the analgesic NaV1.7-selective peptide Pn3a reveals residues essential for membrane and channel interactions
Mueller, Alexander, Dekan, Zoltan, Kaas, Quentin, Agwa, Akello J., Starobova, Hana, Alewood, Paul F., Schroeder, Christina I., Mobli, Mehdi, Deuis, Jennifer R. and Vetter, Irina (2020). Mapping the molecular surface of the analgesic NaV1.7-selective peptide Pn3a reveals residues essential for membrane and channel interactions. ACS Pharmacology and Translational Science. doi: 10.1021/acsptsci.0c00002
2019
Journal Article
Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain: evidence for analgesic synergy with opioids and baclofen
Mueller, Alexander, Starobova, Hana, Morgan, Michael, Dekan, Zoltan, Cheneval, Olivier, Schroeder, Christina I., Alewood, Paul F., Deuis, Jennifer R. and Vetter, Irina (2019). Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain: evidence for analgesic synergy with opioids and baclofen. Pain, 160 (8), 1766-1780. doi: 10.1097/j.pain.0000000000001567
2019
Journal Article
Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathy
Starobova, H., Mueller, A., Allavena, R., Lohman, R. J., Sweet, M. J. and Vetter, I. (2019). Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathy. Frontiers in Neuroscience, 13 (JUN) 653, 653. doi: 10.3389/fnins.2019.00653
2019
Journal Article
Inflammatory and neuropathic gene expression signatures of chemotherapy-induced neuropathy induced by vincristine, cisplatin and oxaliplatin in C57BL/6J mice
Starobova, Hana, Mueller, Alexander, Deuis, Jennifer R., Carter, David A. and Vetter, Irina (2019). Inflammatory and neuropathic gene expression signatures of chemotherapy-induced neuropathy induced by vincristine, cisplatin and oxaliplatin in C57BL/6J mice. The Journal of Pain, 21 (1-2), 182-194. doi: 10.1016/j.jpain.2019.06.008
2019
Conference Publication
New insights in ω-conotoxin analgesic efficacy in postsurgical pain and oxaliplatin/cisplatin induced peripheral neuropathy
Hasan, Mahadhi, Mueller, Alexander, Starobova, Hana, Vetter, Irina, Cardoso, Fernanda C. and Lewis, Richard J. (2019). New insights in ω-conotoxin analgesic efficacy in postsurgical pain and oxaliplatin/cisplatin induced peripheral neuropathy. Brisbane Pain Research Symposium: Multidisciplinary Perspectives & Therapeutics 2019, Brisbane, QLD Australia, 29 November 2019.
2018
Journal Article
Transcriptomics in pain research: insights from new and old technologies
Starobova, H., S. W. A., Himaya, Lewis, R. J. and Vetter, I. (2018). Transcriptomics in pain research: insights from new and old technologies. Molecular Omics, 14 (6), 389-404. doi: 10.1039/c8mo00181b
Supervision
Availability
- Dr Hana Starobova is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
A systematic review of predictors and outcome measures in chemotherapy-induced peripheral neuropathy
Masters Project:
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect without effective treatment options. Up to 90% of paediatric and adult patients treated with chemotherapy develop severe CIPN. This condition not only increases morbidity but also significantly diminishes long term the quality of life for the affected patients. CIPN is very difficult to diagnose in patients, impacting the future understanding of this condition and the development of effective treatment strategies. A vast range of studies addressing CIPN predictors/markers and outcome measures have been published, however, many of these studies contradict each other or are based on poor methodologies. Therefore, in this project, we will aim to perform a systematic review of clinical studies to bring a better understanding of the predictors/markers and outcome measures of CIPN.
Systematic Review, no laboratory work involved.
Supervisors: Dr Hana Starobova, Prof Irina Vetter
-
Modulating Potassium Channels for Immune Cell Activation
Project available from January 2024
Macrophages are innate immune cells that are crucial for initiating immune response. Macrophage activation is implicated in driving many painful pathological stages, including neuropathy and inflammatory pain. Potassium channels, such as Kv1.3, regulate cell potassium homeostasis, and any dysregulation in intracellular potassium can lead to macrophage activation and resultant cytokine and chemokine release, driving pathogenesis of pain. This project will investigate the effects of specific potassium channel-targeting toxins on macrophage activation using electrophysiology techniques, live cell fluorescent microscopy, and in vivo rodent behavioural studies.
Supervisors: Prof Irina Vetter, Dr Hana Starobova
Animal handling and behavioural assessments in rodents are vital for this project.
-
Developing Models of Cancer Therapy-Induced Late Effects
Project available from January 2024
Treatments such as radiotherapy and chemotherapy for childhood and adult brain cancers save many lives. However, they also cause long-term debilitating adverse effects, also termed "late effects", such as pain, cognitive disabilities and sensory-motor neuropathies. Currently, no effective treatments are available, and brain cancer survivors are forced to live with long-term disabilities.
Animal models are important for the understanding of disease pathology and for preclinical testing of novel treatment strategies. However, currently there are no appropriate animal models available for the testing of late effects of cancer therapy.
To address this gap, this PhD project aims to develop in-vivo animal models of cancer therapy-induced late effects and to test the efficacy of novel treatment strategies. This project forms a foundation for future clinical studies.
Project will be performed in collaboration with Prof. Irina Vetter (IMB) and A/Prof. Raelene Endersby (Telethon Kids Institute).
Animal handling and behavioral assessments in rodents are vital for this project.
-
Modulating Potassium Channels for Immune Cell Activation
Project available from January 2024
Macrophages are innate immune cells that are crucial for initiating immune response. Macrophage activation is implicated in driving many painful pathological stages, including neuropathy and inflammatory pain. Potassium channels, such as Kv1.3, regulate cell potassium homeostasis, and any dysregulation in intracellular potassium can lead to macrophage activation and resultant cytokine and chemokine release, driving pathogenesis of pain. This project will investigate the effects of specific potassium channel-targeting toxins on macrophage activation using electrophysiology techniques, live cell fluorescent microscopy, and in vivo rodent behavioural studies.
Supervisors: Prof Irina Vetter, Dr Hana Starobova
Animal handling and behavioural assessments in rodents are vital for this project.
-
A systematic review of predictors and outcome measures in chemotherapy-induced peripheral neuropathy
Masters Project:
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect without effective treatment options. Up to 90% of paediatric and adult patients treated with chemotherapy develop severe CIPN. This condition not only increases morbidity but also significantly diminishes long term the quality of life for the affected patients. CIPN is very difficult to diagnose in patients, impacting the future understanding of this condition and the development of effective treatment strategies. A vast range of studies addressing CIPN predictors/markers and outcome measures have been published, however, many of these studies contradict each other or are based on poor methodologies. Therefore, in this project, we will aim to perform a systematic review of clinical studies to bring a better understanding of the predictors/markers and outcome measures of CIPN.
Systematic Review, no laboratory work involved.
Supervisors: Dr Hana Starobova, Prof Irina Vetter
Supervision history
Current supervision
-
Doctor Philosophy
Developing Models of Cancer Therapy-Induced Late Effects
Associate Advisor
Other advisors: Professor Irina Vetter
-
Doctor Philosophy
Understanding pain mechanisms in the path towards target-specific analgesic agent design
Associate Advisor
Other advisors: Dr Ingrid Winkler, Professor Irina Vetter
-
Doctor Philosophy
Reducing long-term side-effects of chemotherapy in cancer survivors
Associate Advisor
Other advisors: Dr Ingrid Winkler, Professor Irina Vetter
Completed supervision
-
2024
Doctor Philosophy
Immune cell regulation by the microenvironment
Associate Advisor
Other advisors: Honorary Professor Kristen Radford, Dr Ingrid Winkler
Media
Enquiries
For media enquiries about Dr Hana Starobova's areas of expertise, story ideas and help finding experts, contact our Media team: